Overview

Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim

Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
The study will assess the efficacy of LA-EP2006 compared to Neulasta® with respect to the mean duration of severe neutropenia during treatment with myelosuppressive chemotherapy in breast cancer patients.
Phase:
Phase 3
Details
Lead Sponsor:
Sandoz
Collaborator:
Sandoz GmbH
Treatments:
Cyclophosphamide
Doxorubicin
Lenograstim